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Abstract: A new, simple, and microwave-assisted, solution-phase T3P®-DMSO mediated 
method for the preparation of a novel class of estrogen receptor alpha (ERα) ligands based on 
the 2-phenylquinoline scaffold was developed. Furthermore, the novel ERα ligands were 
tested for their bioactivity against ERα-positive and ERα-negative cell lines. The ligand 
(entry 4), with amine and nitro group substitution at C4 position, displayed significant 
cytotoxicity against MCF-7 and HepG2 cells with an IC50 value of 6 and 11 µM, respectively. 
On the other hand, ERα-negative cells displayed resistance to quinolines induced cytotoxicity 
with an IC50 value >100 Μm and they does not induce cytotoxicity in normal breast epithelial 
cells.  Molecular docking analyses suggest a consistent binding mode for these ERα ligands 
in the ligand binding domain of the human ERα and predict the ligands to occupy the 
hydrophobic cavity in a similar fashion as estradiol or GW2368.  
 
  
INTRODUCTION 
 
Breast cancer is a leading cancer in women worldwide and contributing to second cause of 
lethality after lung cancer.1, 2 Most breast cancers are associated with interaction of estrogen 
receptors (ER) in the breast epithelial cells to estrogen. The physiological action of estrogen 
is induced via two types of estrogen receptors namely ERα and ERβ.3 Research in the 
previous decade revealed that more than 70% of breast cancers are due to ERα dependent 
epithelial cell proliferation. The role of ERβ is not clear in initiation and progression of breast 
cancer.4 ERα belongs to nuclear receptor superfamily which regulates the transcription of 
genes involved in proliferation, anti-apoptosis, metastasis and immunosurveillance.5-7 The 
binding of 17β-estradiol to ERα induces the receptor dimerization and facilitates binding of 
the ligand-receptor complex to the promoter of target genes.8  Also, ER-dependent pathways 
regulate the synthesis and distribution of glycosaminoglycans in cancer cells.9 Several small 
molecule ERα antagonists including Tamoxifen, Raloxifene and Fulvestrant have been 
implemented in the treatment of breast cancer.10, 11 Benzisoxazole tethered azoles have 
known to be the better ER ligands.12-14  Therefore, probing small molecules against ERα is 
considered to be the most attractive therapeutic target to treat breast cancer.15  
Quinoline derivatives are the pharmacologically important heterocycles which have been 
studied extensively for their anticancer properties. Multiple reports have demonstrated the 
preparation of quinolines using strong base like tertiary butoxide.16, 17 We  previous reported 
the anti-cancer effect of various heterocyclic compounds 18-20 and recently reported the 
solution phase synthesis of 2-amino-chromene-3-carbonitriles from alcohols, malanonitrile 
and phenols.21 Using a similar strategy, herein, we report a simple and efficient method for 
the preparation of T3P®-DMSO mediated 2-phenylquinoline derivatives using amino 
alcohols and acetophenones under microwave irradiation and evaluated for their cytotoxicity. 
The newly developed method was generalized using variety of aromatic 2-amino alcohols 
  
and different substituted acetophenones to obtain 1-10 molecules (Scheme 2; Table 1).  Our 
docking analysis validated the interaction of quinoline derivatives with the estrogen receptor 
in the similar fashion as estradiol to induce its anticancer effect.  
Table 1. The physical characterization of new quinoline-based ERα ligands, whose core 
scaffold has different substitutions at R1 to R6 positions. 
Entry R1 R2 R3 R4 R5 R6 Y mp 
(0C) 
1 H H OH H H H 85 52 
2 CH3 H Br H H H 89 50 
3 H H Cl H Cl H 92 70 
4 H Cl H H NH2 H 95 60 
5 CH3 H Cl H Cl H 90 59 
6 H H H H Br H 88 63 
7 CH3 H H H H H 87 54 
8 CH3 H H H NH2 H 91 67 
9 CH3 H OH H H OH 89 54 
10 CH3 H H NO2 H H 93 64 
  
Additionally, all the new molecules were characterized completely using IR, 1H NMR, 13C 
NMR, and LC-MS spectral analysis (please refer supplementary data). 
Further, the library of ERα ligands was tested for its cytotoxicity against ERα-positive, ERα-
negative cancer cells and their counterpart non-diseased breast epithelial cells as described 
previously and detailed methodology is provided in supplementary information.22, 23 The 
results are summarized in Table 2.  
 
 
  
Table 2. Cytotoxicity data for the new ERα ligands IC50 against human cancer cells. 
Entry ERα-positive cells 
 
ERα-negative cells Breast epithelial cells 
 
MCF-7 
(µM) 
HepG2 
(µM) 
MDA-MB-231 
(µM) 
BT549 
(µM) 
MCF-10A 
(µM) 
  
1 >50 >50 NT NT NT   
2 >50 >50 NT NT NT   
3 25 31.6 > 100 > 100 > 100   
4 6 11 > 100 > 100 > 100   
5 >50 >50 NT NT NT   
6 12 9 > 100 > 100 60.3   
7 >50 >50 NT NT NT   
8 34 41 NT NT NT   
9 28 19 NT NT NT   
10 23 37 > 100 > 100 > 100   
*NT – Not tested 
Among the tested compounds 4, 6, and 10 significantly inhibited the proliferation of ERα-
positive cells. Further, compounds (4, 6, and 10) with high cytotoxicity were tested against 
ERα-negative cells. All the ERα-negative cells were resistance to the lead compounds with 
IC50 values more than 100 µM. However, the shortlisted three molecules did not induce 
cytotoxicity on MCF-10A cells up to 72 h at 100 µM.  These results indicate that the newly 
synthesized ERα ligands are selectively cytotoxic against ERα expressing cancer cells and 
does not interfere with viability of their counterpart.  
Additionally, the structural models for molecular interactions between the newer ERα ligands 
and the human estrogen receptor were generated using in silico docking analysis as described 
previously and detailed methodology is provided in supplementary information.24-26 Docking 
  
was based on the co-crystal structure of the naphthalene derivative GW2368 with the 
estrogen receptor (PDB: 3DT3).27 Molecular docking suggests a consistent binding mode for 
the series of quinoline-based ERα ligands in the ligand binding domain of the human 
estrogen receptor. Thereby, the compounds occupy the hydrophobic cavity in a similar 
fashion as estradiol or GW2368 (Figure 1). The docking scores of the ERα ligands were 
comparable with estradiol or GW2368 (Supplementary Table 1). The quinoline scaffold of 
the ERα ligands occupies the position of rings A and B in the steroid and show major overlap 
with the naphthalene ring system of GW2368. Furthermore, presence of benzene substituents 
allows for interactions with His-524 in agreement with other estrogen receptor ligands. 
Presence of a hydrogen bond donor function is predicted to facilitate a second binding mode, 
where hydrogen bonds to Arg-394 and Glu-353 are formed. The structure-activity-
relationship studies for the compound 4, which bearing chlorine atom at R2 renders 
significant anti-proliferative activity towards ER positive cancer cells, whereas the presence 
of methyl group at R1 decreases the activity. This observation was evidenced with strong 
binding of compound 4 to ER alpha LBD, when compared to compound 8. 
In conclusion, we have identified a novel quinoline-based ERα ligands as biologically active 
compounds against ERα expressing human cancer cells. This study also introduces a novel 
microwave-assisted synthesis pathway to the compound series. Therefore, method will be 
useful to develop libraries of quinoline-based ERα ligands to treat breast cancer. 
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Figure Legends 
Figure 1: ERα Scaffold Evolution  
Figure 2: Schematic representation of the synthesis of quinoline-based ERα ligands. 
Figure 3: Predicted interactions of quinoline-based ERα molecules towards the ligand 
binding domain of the human estrogen receptor. The protein is shown as green cartoon with 
main polar interaction centers Arg-394, Glu-353, and His-524 highlighted as sticks in atomic 
coloring. Interactions of estradiol with estrogen receptor (A) are resembled by the 
naphthalene-derived compound GW2368 (B) and predicted to be similar for the quinoline 
series (C). 
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